601
Views
5
CrossRef citations to date
0
Altmetric
Original article

Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder

, , &
Pages 629-636 | Accepted 20 Mar 2015, Published online: 22 Apr 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Nan Li, Jian Min Zhuo, Ibrahim Turkoz, Maju Mathews, Yu Feng & Wilson Tan. (2019) A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics. Expert Opinion on Pharmacotherapy 20:16, pages 2033-2039.
Read now
Kruti Joshi, Marie-Hélène Lafeuille, Brianne Brown, Willy Wynant, Bruno Emond, Patrick Lefebvre & Neeta Tandon. (2017) Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting. Current Medical Research and Opinion 33:10, pages 1763-1772.
Read now

Articles from other publishers (3)

Anna Ceraso, Jessie Jingxia LIN, Johannes Schneider-Thoma, Spyridon Siafis, Magdolna Tardy, Katja Komossa, Stephan Heres, Werner Kissling, John M Davis & Stefan Leucht. (2020) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2020:8.
Crossref
Maral DerSarkissian, Patrick Lefebvre, Kruti Joshi, Brianne Brown, Marie-Hélène Lafeuille, Rachel H. Bhak, Michael Hellstern, Priyanka Bobbili, Brian Shiner, Antoine C. El Khoury & Yinong Young-Xu. (2018) Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans. Clinical Therapeutics 40:9, pages 1496-1508.
Crossref
Kruti JoshiJay LinMelissa Lingohr-SmithDong-Jing FuErik Muser. (2016) Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States. Journal of Clinical Psychopharmacology 36:5, pages 429-435.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.